Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphatic Metastasis × Ipilimumab × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 90 Carcinoma, Non-Small-Cell Lung 28 Carcinoma, Renal Cell 19 Prostatic Neoplasms 13 Neoplasm Metastasis 13 Lung Neoplasms 11 Brain Neoplasms 11 Neoplasms 10 Breast Neoplasms 10 Uveal Melanoma 9 Sarcoma 8 Pancreatic Neoplasms 7 Urinary Bladder Neoplasms 6 Small Cell Lung Carcinoma 6 Kidney Neoplasms 6 Carcinoma, Transitional Cell 6 Skin Neoplasms 5 Carcinoma, Hepatocellular 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Colorectal Neoplasms 4 Urogenital Neoplasms 3 Triple Negative Breast Neoplasms 3 Recurrence 3 Rectal Neoplasms 3 Ovarian Neoplasms 3 Neuroendocrine Tumors 3 Mesothelioma, Malignant 3 Mesothelioma 3

Interventions

Radiotherapy, Intensity-Modulated 3 Cisplatin 2 encorafenib 1 binimetinib 1 alovudine 1 X-Rays 1 Specimen Handling 1 Radiosurgery 1 Radiation Dose Hypofractionation 1 Platinum 1 Nivolumab 1 Metastasectomy 1 Magnetic Resonance Spectroscopy 1 Leuprolide 1 Ipilimumab 1 Goserelin 1 Drug Therapy 1 Docetaxel 1 Axitinib 1 Androgen Antagonists 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05504642 2023-04-18

CERAD-IMMUNE

Universitätsklinikum Köln

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡